Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Olaratumab | Whole mAb | G1 | Kappa | Approved | Active | QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | PDGFRA | ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research | Soft tissue sarcoma | Pancreatic cancer;Solid tumours | Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer | Medarex UltiMAb Mouse | null | QL QLQE SGPGL V KPSE TLSLTCTV SGGSINSSS YYWGWLR QSPGKGL EWIGSFFYT GST Y YNPSLR SRLTISVD TSKN QFSLMLSS VTAADT AVYYCA RQS TYYY GSGN YYGWFD RWDQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPAFGQGT KVEI K |
Oleclumab | Whole mAb | G1 | Lambda | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL | na | na | null | null | null | 2,016 | 2017 | NT5E | MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute | na | Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours | Prostate cancer | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAYSWVR QAPGKGL EWVSAIS GSGGR TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED T AVYYC AR LGYG RV DEWGRG TLVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSLSNIGRNPVN WYQ QLPGTAP KLLIYL DNL RL SGVPDRFSGSKSGTS ASLAIS GLQSEDEAD YYCAT WDDSHPGW TF GGGT KLTV L |
Olendalizumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2017 | C5 | Alexion Pharmaceuticals | na | na | Antiphospholipid syndrome;Graft-versus-host disease;Inflammation | na | Olendalizumab is the new name for Lendalizumab (PL116) | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTD YS MDWVR QAPGQGL EWMGAIHLN TGYTNYNQK FKGRVTMTR DTSTS TVYMELS SLRSEDT AVYYCAR GFYDGYSPMDYWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCRA SESVDSYGN SFMHWYQ QKPGKAP KLLIYRA SNLESGVPS R FSGSGSGTD FTLTIS SLQPED F ATYYCQ QSNEDPYTFGGG TKVEI K |
Olinvacimab | Whole mAb | G1 | Lambda | Phase-II | Active | QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS | NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL | na | na | null | null | null | 2,018 | 2019 | KDR | PharmAbcine;3SBio | na | Glioblastoma;Breast cancer | Cancer;Choroidal neovascularisation;Solid tumours | na | Olinvacimab is the new name for Tanibirumab | QM QLVQ SGA EVK KPGA SVKLSCK ASGY TFSSYWMHWVR QAPGQ RLEWMGEI NPGNGHTNYNEKFKS RVTITV DKSAS TAYMELS SLRSEDT AVYYCAKIW GPSLTSPFDYWGQG TLVTVS S | NFMLTQPPS VSV SPGK TARITCR GDNLGD VNVHWYQ QRPGQAP VLVMYY DADRPSGIPERFSGSNSGN TATLTISGV EAGDE ADYYCQVW DRTSE YVF GTGT KVTV L |
Olokizumab | Whole mAb | G4 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK | na | na | 4cni:HL:AB | null | 7si0:CD:IJ:EF:KL | 2,010 | 2011 | IL6 | R-Pharm;UCB | Rheumatoid arthritis;SARS-CoV-2 acute respiratory disease | Inflammation | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGFN FNDYFMNWVRQ APGKG L EWVAQM RNKNYQYG TYYAE SLEG RFTISR DDSKNS LYLQMN SLKTEDT AVYYCA RESYYG FTSY WGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCQ ASQD IGISLSWYQ QKPGKAP KLLIYN ANNLADGVPS RF SGSGSGTD FTLTISS LQPEDF ATYYCLQ HNSAPY T FGQGT KLEI K |
Omalizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK | na | na | 4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL/7shy:EF:IJ:KL:CD | 5g64:IM:HL/6tcq:HL/6tcr:HL/6tcs:AA/ | 7shu:CD:EF/7shz:CD:EF:IJ:KL | 2,000 | 2001 | IGHE | Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis | Allergic asthma;Urticaria | Seasonal allergic rhinitis;Nasal polyps;Mastocytosis;Asthma;Nephritis | Hypersensitivity;Peanut hypersensitivity | na | HC IMGT 71 is V not L as in Jain paper | E VQLVES GGG LV QPGG SLRLSCAV SGY SIT SGY SWNWIR QAPGKGL EWVASITY DGSTNYNPS VKGRITISR DDSKN TFYLQMN SLRAED TAVYYC ARGSHYFG HWHFAVW GQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCR ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAASY LESGVPS RF SGSGSGTD FTLTIS SLQPED F ATYYCQ QSHEDPYTFGQGT KVEI K |
Omburtamab | Whole mAb Radiolabelled | G1 | Kappa | Preregistration | Active | QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA | DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK | na | na | 5cma:BA | null | null | 2,018 | 2019 | CD276 | Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics | na | Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma;Peritoneal cancer | Solid tumours | na | null | Q VQLQQ SGA ELV KPGA SVKLSCK ASGY TFTNYDINWVR QRPEQGL EWIGWIF PGDGSTQ Y NEKFKG KATLTT DTSSST AYMQLS RLTSEDS AVYFCA RQTT ATWFAYW GQG TLVTVS A | D IVMT QSPA TLSV TPGD RVSLSCR ASQS ISDYLHWYQQ KSHESP RLLIKYA SQSISGIPSRFSGSGSGSD FTLSIN SVEPED VGVYYC QNGH SFPLTF GAGT KLEL K |
Omodenbamab | Whole mAb | G3 | Kappa | Phase-I/II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVSSITGSGRSTFYADSVKGRFTISRDNSTNTLSLQMNSLRAEDTAVYYCARSPADIVTGYYPWWFDLWGQGTLVTVSS | DIQMTQSPSSLSASIGDRVTITCRASQSINTYLNWYQQKPGKAPRLLIAGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGQGTRLEIK | na | na | null | null | null | 2,020 | 2021 | SpA | XBiotech Inc. | na | Staphylococcal infections | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFST YG MSWVRQ APGKG LEWVSSI TGSGR STFYA DSVKG RFTISR DNSTN TLSLQMN SLRAEDT AVYYCA RSPAD IVT GYYPW WFD LWGQG TLVTVS S | DIQ M TQSPSS LSA SIGD RVTITCR ASQS INTYLNWYQ QKPGKAP RLLIA GASSLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQANSFP LTF GQGT RLEI K |
Onartuzumab | Fab + di-Fc | G1 | Kappa | Phase-III | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK | na | na | 4k3j:HL | null | null | 2,010 | 2011 | MET | Chugai Pharmaceutical;Genentech | na | na | Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY TFTSYWLHWVR QAPGKGL EWVGMI DPSNSDTRFNPNFKD RFTISA DTSKN TAYLQMN SLRAEDT AVYYCATY RS Y VTPLDYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITC KSSQ SLLYT SSQKN YLAWYQ QKPGKAP KLLIYWAS TRESGVPS RF SGSGSGTD FTLTISS LQP EDFA TYYCQQYY AYPW T FGQGT KVEI K |
Onfekafusp | Whole mAb Fusion | na | Kappa | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | FN extra domain B | Philogen | na | Malignant melanoma;Basal cell cancer;Squamous cell cancer;Solid tumours | na | na | Radretumab+Bifikafusp+Onfekafusp have identical V domains | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSFSMSWVR QAPGKG LEWVSSIS GSSGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPFPYFDYWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSFLAWY Q QKPGQAP RLLIYYA SSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QTGRIPPTFGQGT KVEI K |
Ongericimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLQESGPGLVKPSQTLSLTCTVSGFSISSYGIHWIRQSPGKGLEWIGVIWRGGITDYNAPFMSRVTISKDNSKNQVSFKLSSVTAADTAVYYCANHRDWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDINKYIDWYQHKPGKAPKLLIHYASTLQPGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGQGTKVEIK | na | na | null | null | null | 2,019 | 2020 | PCSK9 | Shanghai Junshi Biosciences | na | Hypercholesterolemia | na | na | null | Q VQLQE SGPGLVKPSQ TLSLTCTV SG FSISSYGIHWIRQ SPGKGL EWIGVIWR GGITDYNAPF MSRVTIS KDNSKN QVSFKLSS VTAADT AVYYCA NHRDWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCQ ASQD INKYIDWY QHKPGKAP KLLIHYA STLQPGVPS R FSGSGSGRD YTFTIS SLQPED I ATYYCLQ YDD LWTF GQGT KVEI K |
Ontamalimab | Whole mAb | G2 | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGINWVRQAPGQGLEWMGWISVYSGNTNYAQKVQGRVTMTADTSTSTAYMDLRSLRSDDTAVYYCAREGSSSSGDYYYGMDVWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK | na | na | 4hcr:MN:HL | null | null | 2,018 | 2019 | MADCAM1 | Pfizer;Takeda | na | na | Crohn's disease;Ulcerative colitis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYGINWVRQ APGQGL EWMGWISVY SGNTNY AQKVQGRVTMTA DTSTS TAYMDLRS LRSDDT AVYYCA REGSSSSGD YYYGMDV WGQG TTVTVS S | DI VMT QTP LSLSV TPGQP ASISC KSSQ SLLH TDGT TYLYWYLQ KPGQPP QLLIYEVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GIYYCMQ NI Q LPW T FGQGT KVEI K |
Ontuxizumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWLQQTPGKAPKLLIYSASNRYTGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYTNYPMYTFGQGTKVQIK | na | na | null | null | null | 2,013 | 2014 | CD248 | Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA) | na | Colorectal cancer;Malignant melanoma;Soft tissue sarcoma | Lymphoma;Solid tumours | na | null | QV QLQE SGPGL V RPSQ TLSLTCT ASGY TFTDYVIHWVK QPPGRG LEWIGYI NPYDDDTTYNQK F KG RVTMLVD TSSN TAYLRLSS VTAEDT AVYYCAR RGNSYDG YFDYSM DYWGSGTP VTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQN VGTAVAWLQ QTPGKAP KLLIYS ASNRYTGVPSRFSGSGSGTD YTFTIS SLQ PEDIATYYCQQ YTNYPM YTF GQGT KVQI K |
Onvatilimab | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSSYGWSYEFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSIDTRLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSAYNPITFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | VSIR | Janssen Research & Development | na | Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR SSYG WSYEFDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQSIDTR LNWYQ QKPGKAP KLLIYS ASSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DFA TYYCQ QSAYNPI T FGQGT KVEI K |
Opicinumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS | DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK | na | na | 4oqt:HL | null | null | 2,015 | 2016 | LINGO1 | Biogen Idec;Dyax;Biogen | na | na | Multiple sclerosis;Optic neuritis | Dyax Human Phage Display | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSAYEMKWVRQ APGKG LEWVSVI GPSGG FTFYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA TEGDNDA FDIW GQG TTVTVS S | DIQ MT QSPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWP MYTF GQGT KLEI K |
Oportuzumab | scFv | na | Kappa | Preregistration | Discontinued | EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS | DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK | na | na | null | null | null | 2,008 | 2009 | EPCAM | University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies | na | na | Bladder cancer;Head and neck cancer;Liver cancer;Ovarian cancer | na | null | E VQLVQ SGPG LV QPGG SVRISC AASGY TFTN YGM NWVK QAPGKGL EWMGWIN TYTGES TY ADSFKG RFTFSL DTSAS AAYLQINSL RAEDT AVYYCARFAIK GDYWGQ GTLLTVS S | DI QMT QSPSS LSA SVGD RVTITCR STK SLLH SNG ITYLYWYQ QKPGKAP KLLIYQM SNLASGVPS RF SSSGSGT DFTLTISS LQPE DF ATYYCA QNLEIPRTFGQGT KVEL K |
Opucolimab | Whole mAb | G1 | Lambda | Phase-I | Discontinued | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQAGAFDRWGQGTMVTVSS | QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGWYQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | PDL1 | Shanghai Henlius Biotech | na | na | Solid tumours | na | null | E VQLVQS GGG LV KPGG SLRLSC AASGF TFSSYTMNWVR QAPGKG LEWVSS ISSGSD YLYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RNE LRWY PQAGAFDRWGQG TMVTVS S | QSV V TQPPSMSAAPGQ RVTISC SGSSSY IE S SYV GWYQ QLPGTAP RLLIY DDDMRPSGIPDRFSGSKSGT SATLAITG LQTGDEA DYYCEIWR SGLGG V FGGGT KLTV L |
Ordesekimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGESLKISCKVSGYFFTTYWIGWVRQMPGKGLEYMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGNWNCFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQRYGSSHTFGQGTKLEIS | na | na | null | null | null | 2,020 | 2021 | IL15 | Genmab;Immunex Corporation;Amgen;Cellimmune | na | Psoriasis;Inflammatory arthritis diseases;Celiac disease | na | na | null | E VQLVQ SGA EVK KPGE SLKISCKV SG YFFTTYWIGWVRQ MPGKGL EYMGII YPGDSDTRYSPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RGGNW NCFD YWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASRRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ RYGSSH T FGQGT KLEI S |
Orilanolimab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | QVQLVQSGAELKKPGASVKLSCKASGYTFTSYGISWVKQATGQGLEWIGEIYPRSGNTYYNEKFKGRATLTADKSTSTAYMELRSLRSEDSAVYFCARSTTVRPPGIWGTGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGQAPRLLISGATSLETGVPSRFSGSGTGKDYTLTISSLQPEDFATYYCQQYWSTPYTFGGGTKVEIK | na | na | 6nha:HL | null | null | 2,018 | 2019 | FCGRT | Syntimmune | na | na | Autoimmune haemolytic anaemia;Autoimmune disorders;Pemphigus | na | null | Q VQLVQ SGA EL KKPGA SVKLSCK ASGY TFTSYGISWVK QATGQG LEWIGEIY PRSGN TYY NEKFKG RATLTA DKSTS TAYMELRSL RSEDS AVYFCAR S TTV RPPGI W GTG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASD HINNWLAWYQ QKPGQAP RLLIS GATSLETGVPSRFSGSGTGKD YTLTIS SLQ PEDFATYYCQQ YWSTPY T FGGGT KVEI K |
Ormutivimab | Whole mAb | G1 | Lambda | Approved | NFD | QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS | QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL | na | na | null | null | null | 2,021 | 2022 | Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1 | North China Pharmaceutical Company | Rabies | na | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F N RYTVNWVRQ APGQGL EWMGGIIPIF GTANYAQ R FQG RLTITA DESTS TAYMELSS LRSDDT AVYFCAR ENLDNSGT YYYFSGWF DPWGQ GTLVTVS S | QSALTQPR S VSGSPGQ SVTISCT GTSSDIGG YNFVSWYQ QHPGKAP KLMIYD ATKRPSGVPDRFSGSKSGN TASLTIS GLQAEDEAD YYCCS YAGDYTPG VVF GGGT KLTV L |
Orticumab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSSISVGGHRTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL | na | na | null | null | null | 2,012 | 2013 | OxLDL | Abcentra;BioInvent International;Genentech | na | Atherosclerosis;Psoriasis | na | Human Phage Display | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF SNA WMSWVR QAPGKGL EWVSSISV GGH RTYYA DSVKG RSTISR DNSKN TLYLQMNS LRAEDT AVYYCARIRV GPSGGA FDYW GQG TLVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSNTN I G KNYVSWYQQ LPGTAP KLLIYA NSNRPSGVPDRFSGSKSGT SASLAIS GLRSEDEAD YYCASW DASLNG WVF GGGT KLTV L |
Osemitamab | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGQGLEWMGNIDPYYGGTSYNQKFKGRVTMTIDKSTSTVYMELSSLRSEDTAVYYCARMYHGNAFDYWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNLKNYLTWYQQKPGQPPKLLIYWASTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | CLDN18 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYNMNWVR QAPGQGL EWMG NIDPYYGGTSYNQKFKG RVTMTID KSTS TVYMELS SLRSEDT AVYYCARMY HGNAFDYWGQG TTVTVS S | D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSGN LKNYLTWYQ QKPGQPP KLLIYWAS TRKSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYSYP LTF GGG TKVEI K |
Osocimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWVRQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADSFPVTFGGGTKVEIK | na | na | null | 6hhc:HL | null | 2,018 | 2019 | F11 | Bayer HealthCare | na | Venous thromboembolism | Arterial thrombosis;Venous thrombosis | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSQ YGM DWVR QAPGKG LEWVS GIGPSGGS TVYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYC TRGGP YYYYGMDV WGQG TTVTVS S | DIQMTQSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYC QQADSFP VTF GGG TKVEI K |
Otelixizumab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS | DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL | na | na | null | null | null | 2,007 | 2008 | CD3E | BTG;GlaxoSmithKline;Tolerx | na | Type 1 diabetes mellitus | Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF SSFP MAWVRQ APGKG LEWVSTIS TSGGR TYYRD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKFR QYSGGFDYWGQG TLVTVS S | DI QLT QPN SVST SLGS TVKLSCTL SSGNIENN YVHWYQLY EGRSPT TMIY DDDKRPDGVPDR FSGSID RSSNS AFLTIHNVAI EDE AIYFCHSYVSSFNVF GGGT KLTV L |
Otilimab | Whole mAb | G1 | Lambda | Phase-III | Active | QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS | DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVL | na | na | null | 5c7x:MN:HL/5d7s:HL | 5d72:MN:HL/5d71:HL | 2,018 | 2019 | CSF2 | GlaxoSmithKline;MorphoSys | na | Rheumatoid arthritis | Inflammation;Multiple sclerosis;Osteoarthritis | MorphoSys HuCAL Phage Display | null | Q VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMNWVR QAPGKGL EWVS GIENKYAGGA TYYAASV KG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RGFGTDFWGQG TLVTVS S | DIELTQPPS VSV APGQ TARISC SGDSIGK KYAYWYQ QKPGQAP VLVIYKK RPSGIPERFSGSNSGN TATLTIS GTQAEDEA DYYCSA WGDKG MVF GGGT KLTV L |
Otlertuzumab | di-scFv+Fc | G1 | Kappa | Phase-II | Discontinued | EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | CD37 | Trubion Pharmaceuticals;Aptevo Therapeutics | na | na | Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma | ADAPTIR Monospecific Platform | null | E VQLVQ SGA EVK KPGE SLKISC KGSGY SFT G Y NMN WVR QMPGKGL EWM GNIDPYYGGTT Y NRK F KG QVTIS ADKS ISTAYLQWSS LKASDT AMYYCARS VGPFDSWGQ GTLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASEN VY SYLA WY QQKPGQAP RLLIYFA KTLA EGIPA RFS GSGSGTD FTLTIS SLEPED FAVYYCQ HHSDNPWTFGQGT KVEI K |
Oxelumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSIISGSGGFTYYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDRLVAPGTFDYWGQGALVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK | na | na | null | null | null | 2,010 | 2011 | TNFSF4 | Genentech;Genmab;Roche | na | na | Allergic asthma;Allergic rhinitis | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFNSYAMSWVR QAPGKGL EWVSIIS GSGG FTYYA DSVKG RFTISR DNSR TTLYLQMN SLRAEDT AVYYC AKDR LV APGT FDY WGQG ALVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATYYCQ QYNSYPY T FGQGT KLEI K |
Ozanezumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS | DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | RTN4 | GlaxoSmithKline | na | na | Amyotrophic lateral sclerosis;Multiple sclerosis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWIGNI NPSNGGTNYNEKFKS KATMTR DTSTS TAYMELS SLRSEDT AVYYCELM QGYWGQG TLVTVS S | D IVMT QSPLSNPVTLGQP VSISC RSSK SLLYK DGK TYLNWFL QRPGQSPQ LLIYLMS TRASGVPDRFSGGGSGT DFTLKISRVE AEDV GVYYCQQLVE YPL T FGQGT KLEI K |
Ozoralizumab | Bispecific Single Domains (VH-VH'-VH) | na;na | na;na | Preregistration | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRGQGTLVTVSS | na | EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS | na | None;None | None;None | 5m2j:D;None | 2,011 | 2012 | TNFA;ALB | Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical | na | Rheumatoid arthritis | Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis | Nanobody Technology | null | E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YWMYWVRQ APGKGL EWVSEI NTNGL ITK YPDSVK GRFTISR DNAKN TLYLQMN SLRPEDT AVYYCAR SPSGFNRGQ GTLVTVS S | null |
Ozuriftamab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGESLRISCKGSGYTFTEYTMHWVRQAPGQGLEWMGGINTNNGGTGYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGSLYSYGNSYFDYWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCSATSSVSYMHWYLQKPGQSPQLLIYGTSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQRSSYPFTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | ROR2 | BioAtla | na | Malignant Melanoma;Non-small cell lung cancer;Ovarian cancer;Solid tumours | na | TBC | null | E VQLVQ SGA EVK KPGE SLRISC KGSGY TFTEYTMHWVRQ APGQG LEWMGGIN TNNGGTGYNQK F K GRVTIS ADKS ISTAYLQWS SLKASDT AMYYC AHGS LYSY GNS YF DYWGQG TLVTV SS | AI QLT QSPSS LSAS VGD RVTITCS ATSS VSYMHWYL QKPGQSP QLLIYG TSNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCQ QRSSYPF TF GQGT KVEI K |
Pabinafusp | Whole mAb Fusion | G1 | Kappa | Approved | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQWSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | TFRC | JCR Pharmaceuticals | Mucopolysaccharidosis II | na | na | na | null | E VQLVQ SGA EVK KPGE SLKISC KGSGYS F T NYWLGWVR QMPGKGL EWMGDI YPGGDYPTYSEK FKVQVTIS ADKS ISTAYLQWS SLKASDT AMYYCA RSGNYD EVAYW GQG TLVTVS S | DI VMT QTP LSLSV TPGQP ASISCR SSQ SLVH SNGN TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K |
Pacanalotamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | TNFRSF17;CD3E | Amgen | na | Multiple myeloma | na | BiTE Technology | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT N HIIHWVR QAPGQGL EWMGYI NPYPGYHAYNEKFQG RATMT SDTSTS TVYMELS SLRSEDT AVYYCA RDGY Y RDTD VLDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLHTGVPSRFSGSGSGTD FTFTIS SLE PEDIATY YC QQGNTLPW TF GQGT KVEI K |
Pacmilimab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | PDL1 | CytomX Therapeutics | na | Solid tumours;Lymphoma | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSSIWR NG IVTVYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK WSAA F DYWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QDNGYPSTFGGG TKVEI K |
Palivizumab | Whole mAb | G1 | Kappa | Approved | NFD | QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS | DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK | na | na | null | 2hwz:HL | null | 1,998 | 1999 | RSV gpF | MedImmune | Respiratory syncytial virus infections | na | na | GS Gene Expression System | null | Q VTLRE SGPA LV KPTQ TLTLTCTF SG FSL STSG MSVGWIR QPPGKA LEWLADIWW DDKKDYNPSLK SRLTIS KDTSKN QVVLKVTN MDPADTA TYYCA RSMITN WYFDVW GAGT TVTVS S | DI QMT QSPS TLSAS VGD RVTITCKCQLSV G YMHWYQ QKPGKAP KLLIYD TSKLASGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCF QGSGYP FTF GGGT KLEI K |
Pamrevlumab | Whole mAb | G1 | Kappa | Phase-III | Active | EGQLVQSGGGLVHPGGSLRLSCAGSGFTFSSYGMHWVRQAPGKGLEWVSGIGTGGGTYSTDSVKGRFTISRDNAKNSLYLQMNSLRAEDMAVYYCARGDYYGSGSFFDCWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | CTGF | FibroGen | na | Duchenne muscular dystrophy;Idiopathic pulmonary fibrosis;Pancreatic cancer | Diabetic cardiomyopathy;Diabetic nephropathies;Diabetic neuropathies;Glioblastoma;Glomerulonephritis;Hepatic fibrosis | na | null | EG QLVQS GGG LV HPGG SLRLSC AGSG FTFS SYG MHWVRQ APGKG LEWVSGI GTGGG TYS TDSVK GRFTIS RDNAKN SLYLQMNS LRAEDM AVYYCA RGDYYGSGS FFD CWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISSWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQ PEDFATY Y CQQ YNSYPPTFGQGT KLEI K |
Panitumumab | Whole mAb | G2 | Kappa | Approved | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK | na | na | 5sx5:HL:JK/5sx4:HL:JI | null | null | 2,004 | 2005 | EGFR | Amgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma | Colorectal cancer | Anal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer | Head and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours | Abgenix XenoMouse | null | Q VQLQE SGPGL V KPSE TLSLTCTVS GGSVSSGD YYWTWIRQ SPGKGL EWIGHIYYS GNTNYNPSLK SRLTISID TSKT QFSLKLSS VTAADT AIYYCVR DRVTG AFDIW GQG TMVTVS S | DIQMTQSPSS LSA SVGD RVTITCQ AS QDISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYFCQH FDHLP LAF GGGT KVEI K |
Panobacumab | Whole mAb | M | Kappa | Phase-II | Active | EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS | DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK | na | na | null | null | null | 2,008 | 2009 | Serotype IATS O11 | Berna Biotech;Aridis Pharmaceuticals | na | Nosocomial pneumonia | na | na | null | EE QVVES GG GFV QPGG SLRLSCA ASGF TF SPY WMHWVR QAPGKG LVWVSRI NSDGS TYYAD SVKG RFTISR DNARN TLYLQMNS LRAEDT AVYYCA RDRYYGPEMWGQG TMVTVS S | DV VMT QSPLSLP VT LGQP ASISC RSSQ SLVY SDGN TYLNWFQ QRPGQSPR RLIYKVS NRDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCM QGTHWP LTF GGG TKVEI K |
Paridiprubart | Whole mAb | G1 | Kappa | TBC | Active | QVQLQESGPGLVKPSDTLSLTCAVSGYSITGGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITISRDTSKNQFSLKLSSVTAVDTAVYYCARKDPSDAFPYWGQGTLVTVSS | EIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPDQSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGHSFPLTFGGGTKVEIK | na | na | 4r7d:AB:CD:EF:GH:IJ:MN:OP | null | 4r7n:AB:CD:EF:GH:IJ:MN:OP:QR:ST | 2,022 | na | TLR4 | TBC | TBC | COVID-19 | TBC | TBC | null | QV QLQ ESGPGL V KPSD TLSLTCAV SGY SIT GG YSWHWIR QPPGKGL EWMGYIHY SGYTDFNPSL KTRITISR DTSKN QFSLKLSSVTA VD TAVYYCAR KDPSDAFPYWGQG TLVTV SS | E IVLTQ SPDFQSVTPKE KVTITCR ASQS ISDHLHWY QQKPDQSPK LLIKYA SH AI SGVPSRFSGSGSGTD FTLTIN SLE AEDAATY YC QQGHSFP LTF GGGT KVEI K |
Parsatuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | EGFL7 | Chugai Pharmaceutical;Genentech | na | na | Colorectal cancer;Non-small cell lung cancer;Solid tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY TFID YYMNW VR QAPGKGL EWVGDINL DNSGTHYNQK FKGRFTISR DKSKN TAYLQMN SLRAEDT AVYYCA REGV Y HDYDDYA M DYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR TSQS LVHINAITYLHWY QQKPGKAP KLLIYRVS NRFSGVPSRFSGSGSGT DFTLTISS LQPE D F ATYY CGQST HVPLT FGQGT KVEI K |
Pasotuxizumab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I | Discontinued | QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYRYSDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDSYPYTFGGGTKLEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,014 | 2015 | FOLH1;CD3E | Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc | na | na | Prostate cancer | na | null | Q VQLVES GGG LV KPGE SLRLSCA ASGF TF SD YYMYWVRQ APGKG LEWVAIIS DGG YYTYYS DI I KG RFTISR DNAKNS LYLQMN SLKAEDT AVYYC ARGFP LLR HGAMDYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGQAPK SLIYSASYR YSDVPSRFSGSASGTD FTLTISS VQSEDF ATYYCQ QYDSYPY T FGGGT KLEI K |
Pateclizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK | na | na | 4mxv:HL:YX:FE/4mxw:HL:WV | null | null | 2,011 | 2012 | LTA | Genentech | na | na | Rheumatoid arthritis | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY TFTSYVIHWVR QAPGKG LEWVGY NNPYNAGTNYNEKFK GRFTISS DKSKN TAYLQMN SLRAEDT AVYYC SRPTMLP WFAYW GQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQA VSSA VAWYQ QKPGKAP KLLIYS ASHR Y TGVPSRFSGSGSGTD FTLTIS SLQPE DFA TYYC QESYSTPW T FGQGT KVEI K |
Patritumab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS | DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK | na | na | null | null | null | 2,011 | 2012 | ERBB3 | Amgen;U3 Pharma;Daiichi Sankyo Company | na | Non-small cell lung cancer;Head and neck cancer;Breast cancer | Solid tumours | na | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLKS RVTISVE TSKN QFSLKLSS VTAADT AVYYCA RDKW TWYFDL WGRG TLVTVS S | DIE M TQSPDS LAVS LGE RATINC RSSQ SVLYS SSNRN YLAWYQ QNPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYSTPRTFGQGT KVEI K |
Pavurutamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGCGTKVEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | TNFRSF17;CD3E | Amgen | na | Multiple myeloma | na | BiTE Technology | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT N HIIHWVR QAPGQ CLEWMGYI NPYPGYHAYNEKFQG RATMT SDTSTS TVYMELS SLRSEDT AVYYCA RDGY Y RDTD VLDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLHTGVPSRFSGSGSGTD FTFTIS SLE PEDIATY YC QQGNTLP WTF GCGT KVEI K |
Pelgifatamab | Whole mAb ADC | G1 | Kappa | Phase-I | Active | QVQLVESGGGVVQPGRSLRLSCAASGFAFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCARGGDFLYYYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKTGKVPKFLIYEASTLQSGVPSRFSGGGSGTDFTLTISSLQPEDVATYYCQNYNSAPFTFGPGTKVDIK | na | na | null | null | null | 2,020 | 2021 | FOLH1 | Bayer | na | Prostate cancer;Metastatic cancers | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF AF SRY GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKNT QYLQMNSL RAEDT AVYYCA RGGD FLYYYYY G M DVWGQG TTVTVS S | DIQMTQSPSS LSA SVGD RVTITCR ASQG ISNYLAWYQQK TGKVP KFLIYE ASTLQSGVPSRFSGGGSGTD FTLTIS SLQ PEDVATYYCQ NYNSAPF T FGPGT KVDI K |
Pembrolizumab | Whole mAb | G4 | Kappa | Approved | Active | QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK | na | na | 5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC | null | null | 2,013 | 2014 | PDCD1 | Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society | Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma | Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections | na | na | Pembrolizumab is the new name for Lambrolizumab (PL110) | Q VQLVQ SG VEVK KPGA SVKVSCK ASGY TFTNYYMYWVRQ APGQG LEWMGGI NPSNGGTNFNEKFKN RVTLTT DSSTT TAYMELKSL QFDDT AVYYCAR RDY RF D MGFD YWGQG TTVTVS S | E IVLT QSPA TLSL SPGE RATLSCRA SKGVSTSGY SYLHWY QQKPGQAP RLLIYL ASY LESGVP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ HSRDLP LTF GGGT KVEI K |
Penpulimab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS | DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK | na | na | null | null | null | 2,020 | 2021 | PDCD1 | Akeso Biopharma;Chia Tai Tianqing Pharmaceutical | Hodgkin's disease | Non-small cell lung cancer;Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Head and neck cancer;Liver cancer;Nasopharyngeal cancer;Neuroendocrine tumours;Urogenital cancer;Solid tumours | null | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF AFSS YDM SWVR QAPGKGLD WVATI SGGG RYTY YPDSVK GRFTISR DNSKNN LYLQMN SLRAEDT ALYYCA NRYGE AWFAYW GQG TLVTV SS | DIQ MT QSPSSM SA SVGD RVTFTCR ASQD INTYLSWFQ QKPGKSPK TLIYRA N RLV SGVPS R FSGSGSGQD YTLTISS LQPEDM A TYYCLQ YDEFP LTF GAGT KLEL K |
Pepinemab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | SEMA4D | Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex | na | Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer | Multiple sclerosis | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGYSFSD YYMHWVRQ APGQG LEWMGQI NPTTGGASYNQKFKG KATITVD KSTS TAYMELS SLRSEDT AVYYCARYY YGR HFDVW GQG TTVTVS S | D IVMT QSPDS LAVS LGER ATINCK ASQ SV DYDGD SYMNWYQ QKPGQPP KLLIYAA SNLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSNEDPY T FGQGT KLEI K |
Perakizumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKSLIVRANRLVDGVPSRFSGSGSGQDYSLTISSLQPEDFATYYCLQYDAFPPYTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | IL17A | Roche | na | na | Psoriatic arthritis | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YTMLWVRQ APGKG LEWVAIIK SGGS YSY YPDSVK GRFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RDGDYGSSYG AM DYWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQD INSYLSWFQ QKPGKAPK SLIVRANRLV DGVPS R FSGSGSGQD YSLTIS SLQPEDF ATYYCLQ YDAFPPYTFGQGT KLEI K |
Perenostobart | Whole mAb | G4 | Kappa | TBC | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSEGISWVRQAPGQGLEWMGSILPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAGYYRYRYFDLWGRGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHALWPLTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | ENTPD1 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FS SEG ISWVRQ APGQGL EWMGSILPIF GTANYA Q KFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCAR EAGY YRYRYFDL WGRG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYC QQHALWP LT FGGGT KVEI K |
Peresolimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKVSGYSLSKYDMSWVRQAPGKGLEWMGIIYTSGYTDYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGNPYYTNGFNSWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQSPNNLLAWYQQKPGKAPKLLIYGASDLPSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNNYYVGPVSYAFGGGTKVEIK | na | na | null | null | null | 2,022 | na | PDCD1 | Eli Lilly | na | Rheumatoid arthritis;Plaque Psoriasis | na | TBC | (June '22: Corrected CDRH3 sequence) | Q VQLVQ SGA EVK KPGA SVKVSCKV SGY S LSKY DMSWVR QAPGKGL EWMGIIYT SGYTDY AQ KFQG RVTMT EDTSTD TAYMELSS LRSEDT AVYYC ATGNPYYTNGFNSWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCQ ASQSPN NLLAWY Q QKPGKAP KLLIYG ASDLPSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YC QNN YYV GP VSYA FGGG TKVEI K |
Pertuzumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK | na | na | 1l7i:HL/4llu:AB:CD/1s78:FE:DC/6oge:CB | null | 4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL | 2,003 | 2004 | ERBB2 | Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group | Breast cancer | Ovarian cancer;Brain metastases;Colorectal cancer | Gastric cancer;Non-small cell lung cancer;Prostate cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFT DY TMDWVR QAPGKG LEWVADV NPNSGGS IY NQRFKG RFTLSVD RSKN TLYLQMNS LRAEDT AVYYCA RNLGPS FYFDY WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQD VSIGVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTISS LQPE DFA TYYCQQYYIYP Y T FGQGT KVEI K |
Petosemtamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-I | Discontinued | QVQLVQSGSELKKPGASVKISCKASGYDFTNYAMNWVRQAPGHGLEWMGWINANTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDSAVYYCTRERFLEWLHFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK | EVQLVQSGSKLKKPGASVKVSCKASGYTFTSYTMNWVRQAPGQGLEWMGWINTDTGDPTYAQGFTGRFVFSLDTSVSTAFLQINSLKAEDTAVYYCARGDCDSTSCYRYSYGYEDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK | None;None | None;None | None;None | 2,019 | 2020 | EGFR;LGR5 | Merus | na | na | Colorectal cancer;Solid tumours | na | null | Q VQLVQ SGS E LKKPGA SVKISCK ASGYDFT NY AMNWVR QAPGHGL EWMGWIN ANTGDPTYAQGF TGRFVFSL DTSVS TAYLQISS LKAEDS AVYYCT RE RFLE WLHFD YWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYCQ QSYSTPPTFGQGT KVEI K |
Pexelizumab | scFv | na | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK | na | na | null | 5i5k:HL:XY | null | 2,002 | 2002 | C5 | Stanford University | na | na | Myocardial infarction;Reperfusion injury | na | Same VH as eculizumab | Q VQLVQ SGA EVK KPGA SVKVSCK ASG YIF SN YWIQWVR QAPGQG LEWMGEI LPGSGST EYT ENFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCARYF FGSSPN WYFDVW GQG TLVTVS S | DIQMTQSPSSL SA SVGD RVTITC GASEN IYGALNWY QRKPGKAP KLLIYG ATNLADGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQN VLNTPL T FGQGT KVEI K |
Pidilizumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS | EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK | na | na | null | null | null | 2,012 | 2013 | PDCD1 | American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center | na | Acute myeloid leukaemia;Colorectal cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Malignant melanoma;Multiple myeloma;Pancreatic cancer;Prostate cancer;Renal cell carcinoma;Glioma;Hepatitis C;Liver cancer | na | na | null | Q VQLVQ SGS E LKKPGA SVKISCK ASGY TFTN YG MNWVRQ APGQG LQWMGWIN TDSGES TYAEEF KG RFVFSL DTSVN TAYLQITSL TAEDTG MYFCVRVG YDALDYWGQG TLVTVS S | E IVLT QSPSS LSA SVGD RVTITCS ARSS VSYMHWF QQKPGKAP KLWIYRT SNLASGVPSRFSGSGSGT SYCLTI NSLQ PEDFAT YYC QQRSSFP LTF GGGT KLEI K |
Pimivalimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFPSYYMHWVRQAPGQGLEWMGIINPEGGSTAYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGTYYDYTYWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSFPPTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | PDCD1 | Jounce Therapeutics | na | Solid tumours;Non-small cell lung cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYTFPS YYMHWVRQ APGQG LEWMGII NPEGGST AYAQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYC ARGG TYYDYTY WGQG TLVTVS S | DIQMTQSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYE ASSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FAT YYCQ QYNSFPPTFGGGT KVEI K |
Pimurutamab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFSLTNYGVHWVRQAPGKGLEWLGVIWSGGNTDYGNEFTSRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARALDYYDYEFAYWGQGTMVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQNNNWPTSFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | EGFR | Shanghai Henlius Biotech | na | Solid tumours | na | na | (June '22: Corrected FWH2 sequence) | E VQLVES GGG LV QPGG SLRLSC AASGF SL TNY GVHWVRQ APGKGL EWLGVIWS GGNTDYGNE FTSRFTIS RDNAKN SLYLQMNS LRAEDT AVYYCA RALDYYD YEFAYW GQG TMVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQSIGT NIHWYQ QKPGQAP RLLIKYA SESISGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QNNNWPTSFGGG TKVEI K |
Pinatuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK | na | na | null | 6and:HL | null | 2,012 | 2013 | CD22 | Genentech | na | na | Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY EFS RS WMNWVR QAPGKG LEWVGRI YPGDGDTNYSG KFKGRFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RDGSSW DWYFDV WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR SSQS IVHSV GNT FLE WYQ QKPGKAP KLLIYKV SNRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCF QGSQFPY T FGQGT KVEI K |
Pivekimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYNDGTKYNEKFKGRATLTSDRSTSTAYMELSSLRSEDTAVYYCAREGGNDYYDTMDYWGQGTLVTVSS | EIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYRVNRLVDGVPSRFSGSGSGNDYTLTISSLQPEDFATYYCLQYDAFPYTFGQGTKVEIK | na | na | null | null | null | 2,021 | 2022 | IL3RA | ImmunoGen | na | Acute myeloid leukaemia;Blastic plasmacytoid dendritic cell neoplasm | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSC KASG YIFTS S IMHWVR QAPGQG LEWIGYIK PYNDGTKYNE KF KG RATLTS DRSTS TAYMELS SLRSEDT AVYYCAR EGGNDY Y DT M DYWGQG TLVTVS S | EI QMT QSPSS LSA SVGD RVTITCR ASQD INSYLSWFQ QKPGKAPK TLIYRVNRLV DGVPS RF SGSGSGND YTLTISS LQPEDF ATYYCLQY DAFPY T FGQGT KVEI K |
Placulumab | Single Domain Variable Fragment (VL) + Fc | G1 | Kappa | Phase-II | Discontinued | na | DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLIYSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | TNFA | Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries | na | na | Inflammation;Psoriasis;Rheumatoid arthritis;Sciatica | na | null | null | DIQ MT QSPSS LSA SVGD RVTITCR AS QAIDSYLHWYQ QKPGKAP KLLIYS ASNLETGVPSRFSGSGSGTD FTLTISS LLPE DFA TYYCQQVVWR PFTFGQGT KVEI K |
Plamotamab | Bispecific Mixed mAb and scFv | G1;G1 | Kappa;Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS | QIVLTQSPSSLSASVGDRVTITCRASSSVSYIHWFQQKPGKSPKPLIYATSNLASGVPVRFSGSGSGTDYTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK | None;None | None;None | None;None | 2,018 | 2019 | MS4A1;CD3E | Xencor | na | B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGAI YPGNGDTSYNQ KF Q GRVTIT ADKS ISTAYMELS SLRSEDT AVYYCAR S T YYGGD WYFNVW GAG TLVTVS S | Q IVLT QSPSS LSA SVGD RVTITCR ASSS VSYIHWFQ QKPGKSPKP LIYAT SNLASGV PVRFS GSGSGTD YTLTISS LQPED F ATYYCQQW TSNPPTFGGG TKVEI K |
Plonmarlimab | Whole mAb | G1 | Kappa | Phase-II/III | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHYLHWVRQAPGQGLEWMGWIFPGDDKTKYNEKFKGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTKYLNWNFDVWGQGTTVTVSS | DIQLTQSPSFLSASVGDRVTITCKANQNVGTTLAWYQQKPGKSPKALIYSASYRYSGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCHQYTTYPLTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | CSF2 | I-Mab Biopharma | na | Rheumatoid arthritis;COVID-19;Osteoarthritis | na | na | (June '22: Corrected FWL4 sequence) | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSHYLHWVR QAPGQGL EWMGWI FPGDDKTKYNEKFKG RVTMT SDTS ISTAYMELSR LRSDDT AVYYC ARGT KYLNWNFDV WGQG TTVTVS S | DI QLT QSPS FLSA SVGD RVTITCK ANQNVG TTLAWYQ QKPGKSPK ALIYSASYRY SGVPDRFSGSGSGTD FTLTISS LQP EDFA TYFCH QYTTYP LTF GGG TKVEI K |
Plozalizumab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS | DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK | na | na | null | null | null | 2,015 | 2016 | CCR2 | Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology | na | Atherosclerosis;Diabetic nephropathies;Malignant melanoma | Multiple sclerosis;Rheumatoid arthritis;Scleroderma;Solid tumours | Humanization by CDR Grafting | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSAYAMNWVR QAPGKG LEWVGRIRT KNNNY ATYYA DSVKD RFTISR DDSKN TLYLQMN SLKTEDT AVYYCTTFY GNGV W G QGTLVTVS S | DV VMT QSPLSLPV T LGQPA SISC KSSQ SLL DSDGK TFLNWFQ QRPGQSPR RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCW QGTHFPY T FGQGT RLEI K |
Polatuzumab | Whole mAb ADC | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | CD79B | Chugai Pharmaceutical;Genentech;Roche | Diffuse large B cell lymphoma | Non-Hodgkin's lymphoma;Follicular lymphoma | Chronic lymphocytic leukaemia | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY TFSSYWIEWVR QAPGKGL EWIGEI LPGGGDTNYN EIF KG RATFSA DTSKN TAYLQMN SLRAEDT AVYYCT RRVP IRLDY WGQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCK ASQS V DYEGD SFLN W Y QQKPGKAP KLLIYAA SNLESGVPS R FSGSGSGTD FTLTIS SLQPED F ATYYCQ QSNEDPL T FGQGT KVEI K |
Polzastobart | Whole mAb | G4 | Kappa | TBC | Active | QITLKESGPTLVKPTQTLTLTCTFSGFSLNTYAMGVSWIRQPPGKALEWLASIWWNGNKYNNPSLKSRLTVTKDTSKNQVVLTMTNMDPVDTATYYCAHSRIIRFTDYVMDAWGQGTLVTVSS | DIQMTQSPSSLSTSVGDRVTITCRASEDIYNDLAWYQQKPGKAPKLLIYNANSLHTGVASRFSGSGSGTDFTFTISSLQPEDVATYFCQQYYDYPLTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | LILRB2 | TBC | TBC | TBC | TBC | TBC | null | Q ITLK ESGP TLV KPTQ TLTLTCTF SGFSLN TYAMGVSWIR QPPGKA LE WLASIWW NGNKYNNPSLK SRLTVTK DTSKN QVVLTMT NMDPVDTA TYYC AHSR IIRFT D YVM DAWGQG TLVTVS S | DIQ MT QSPSSL S TSVGD RVTITCR AS EDIYNDLAWYQ QKPGKAP KLLIYN ANSLHT GVASR FSGSGSGT DFTFTIS SLQ PEDVATYFCQQY YDYPL T FGQGT KLEI K |
Ponezumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS | DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK | na | na | 3u0t:BA:DC | null | null | 2,010 | 2011 | APP | Rinat Neuroscience;Pfizer | na | na | Alzheimer's disease;Cerebral amyloid angiopathy | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY YTEAYYIHWVR QAPGQG LEWMGRI DPATGNTKYAPRLQD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCASL YSLP VYW GQGT TVTVS S | DV VMT QSPLSLPVTLGQPA SISC KSSQS LLY SD AKTYLNWFQ QRPGQSPR RLIYQISR LDPGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCL QGTHYP VLF GQGT RLEI K |
Ponsegromab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYNIDWVRQAPGQGLEWMGGINPIFGTAFYNQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAITTVGAMDHWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRTSQSVHNYLAWYQQKPGQAPRLLIYDASTRADGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFWSWPWTFGQGTKVEIK | na | na | null | null | null | 2,020 | na | GDF15 | Pfizer | na | na | Cachexia | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFSSYNIDWVR QAPGQGL EWM GGINPIFG TAFY NQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RE AITTV GAMDHWGQG TLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR TSQS VHNYL A W Y QQKPGQAP RLLIYD ASTRADGI PARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QFWSWPWTFGQGT KVEI K |
Porustobart | VH-CH2-CH3 | G1 | na | TBC | Active | EVQLVESGGGLIQPGGSLRLSCAVSGFTVSKNYMSWVRQAPGKGLEWVSVVYSGGSKTYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPHSPSSFDIWGQGTMVTVSS | na | na | na | 7dv4:H:B:D:F | null | null | 2,022 | na | CTLA4 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LI QPGG SLRLSCAV SG FTV SKN YMSWVR QAPGKGL EWVSVVYS GGSKTYADSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCARA VPHSPSS FDIW GQG TMVTVS S | null |
Posdinemab | Whole mAb | G1 | Kappa | TBC | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISKGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGWGDYGWFAYWGQVTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDINRYLNWFQQKPGKAPKSLIYRANRLLDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQYDEFPLTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | MAPT | TBC | TBC | TBC | TBC | TBC | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVASIS KGGN TYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCA RGWGDYG WFAYW G QVTLVTV SS | DIQ M TQSPSS LSA SVGD RVTITCK AS QDINRYLNWFQ QKPGKAP KSLIYRANRL LDGVPS R FSGSGSGTD FTLTIS SLQPEDF ATYYCLQ YDEFPL T FGQGT KLEI K |
Pozelimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLQESGPGLVKPSETLSLTCTVSGDSVSSSYWTWIRQPPGKGLEWIGYIYYSGSSNYNPSLKSRATISVDTSKNQFSLKLSSVTAADTAVYYCAREGNVDTTMIFDYWGQGTLVTVSS | AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFAGRGSGTDFTLTISSLQPEDFATYYCLQDFNYPWTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | C5 | Alnylam Pharmaceuticals;Regeneron Pharmaceuticals | na | Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria;Gastrointestinal disorders | na | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SGDSVS SSYWTWIR QPPGKGL EWIGYIYYS GSSNYNPSLK SRATISVD TSKN QFSLKLSS VTAADT AVYYCA REGNVD TTMIFD YWGQG TLVTVS S | AI QMT QSPSS LSAS VGD RVTITCR ASQGIRNDLG WYQ QKPGKAP KLLIYAA SSLQSGVPS RF AGRGSGTD FTLTISS LQPEDF ATYYCL QDFNYPW T FGQGT KVEI K |
Plutavimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSIIYPGGSTEYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARELGYYGMDVWGQGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISTWLVWYQQKPGKAPNLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANAYPYTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | SARS-CoV-2 Spike RBD | Sorrento Therapeutics | na | COVID-19 | na | na | null | E VQLVES GGG LI QPGG SLRLSC AASGF TVS SN YMSWVR QAPGKG LEWVSII YPGGSTEYADSVK GRFTISR DNSRN TLYLQMNS LRAEDT AVYYC ARE LGYY GMDV WGQG TTVTVS S | DI QMT QSPSS VSAS VGD RVTITCR ASQG ISTWLVWYQ QKPGKAPN LLIYG ASSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QANAYPY T FGQGT KLEI K |
Porgaviximab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS | DIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK | na | na | null | 5kel:HL:PT:QU | null | 2,016 | 2017 | Zaire Ebolavirus GP | Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases | na | na | Ebola virus infections | Zmapp Technology | null | E VQLQE SGGG LM QPGGS MKLSCVA SGF TF SNY WMNWVR QSPEKGL EWVAEIRLK SNNYA THYAES VKG RFTISR DDSKR SVYLQMNTLR AEDT GIYYCT RGNGN YRAMD YWGQG TSVTVS S | DIQ M TQSPA SLSVS VGE TVSITCR ASEN IYSSLAWYQQ KQGKSPQ LLVYSATILA DGVPS RF SGSGSGT QYSLKIN SLQSEDFG TYYCQHF WGTPY T FGGGT KLEI K |
Pradusinstobart | Whole mAb | G4 | Kappa | TBC | Active | QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGTCVSWIRQPPGKALEWLATICWEDSKGYNPSLKSRLTISKDTSKNQAVLTMTNMDPVDTATYYCARREDSGYFWFPYWGQGTLVTVSS | NIQMTQSPSSLSASVGDRVTITCKAGQNVNNYLAWYQQKPGKAPKVLIFNANSLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSWTTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | PDCD1 | TBC | TBC | TBC | TBC | TBC | null | Q VTLK ESGPA LV KPTQ TLTLTCTF SG FSL STSG TCVSWIR QPPGKA LEWLATICWE DSKGYNPSLK SRLTIS KDTSKN QAVLTMT NMDPVDT ATYYCARR EDSG YFWF PYWGQG TLVTVS S | NIQ M TQSPSS LSA SVGD RVTITCK AGQN VNNYLAWYQ QKPGKAP KVLIFN ANSLQTGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YNSW TT FGGGT KVEI K |
Prafnosbart | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGSTFSNYGMKWIRQAPGKGLEWVSSISRSSTYIYYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAAISTPFYWYFDFWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCLASSSVSYMTWYQQKPGQSPRLWIYGTSNLASGVPDRFSGSGSGTDFLTLTIRLEPEDFAVYYCLHLTSYPPYTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | ACVR1 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSCA ASGSTFSNY GMKWIRQ APGKG LEWVSSI SRSS TYIYYA DTVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAAAI STPF YWYFDF WGQG TLVTVS S | E IVLTQ SPG TLSL SPGER ATLSCL ASSS VSYMTWYQ QKPGQSP RLWIYG TSNLASGVPDRFSGSGSGTD FLTLTIRL EPEDF AVYYCLHLT SYPPYTFGQGT KVEI K |
Praluzatamab | Whole mAb | G1 | Kappa | Phase-II | Active | QITLKESGPTLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWSEDKHYSPSLKSRLTITKDTSKNQVVLTITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | CD166 | CytomX Therapeutics;Immunogen | na | Solid tumours | na | na | null | Q ITLK ESGP TLV KPTQ TLTLTCTF SGF SLSTYGMGVGWIR QPPGKA LE WLANIWW SEDKHYSPSLK SRLTITK DTSKN QVVLTITN VDPVDT ATYYCVQID YGND YAFTYW GQG TLVTVS S | DI VMT QSPLSLPVTPGEPA SISCR SSK SLLH SNG ITYLYWYLQ KPGQSP QLLIYQM SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCA QNLELPY T FGQGT KLEI K |
Prasinezumab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASISSGGGSTYYPDNVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARGGAGIDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKSIQTLLYSSNQKNYLAWFQQKPGKAPKLLIYWASIRKSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQYYSYPLTFGGGTKLEIK | na | na | null | null | null | 2,017 | 2018 | SNCA | Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche | na | Parkinson's disease | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS NYG MSWVRQ APGKG LEWVASIS SGGGST Y YPDNVK GRFTISR DDAKNS LYLQMN SLRAEDT AVYYCA RGGAG IDY WGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITC KS IQTLLY SSNQK NYLAWFQ QKPGKAP KLLIYWASI RKSGVPS RF SGSGSGTD FTLTIS SLQ PEDLATYYCQQ YYSYP LTF GGGT KLEI K |
Prezalumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK | na | na | 6x4t:BE:DF | null | null | 2,015 | 2016 | ICOSLG | Amgen;MedImmune | na | na | Cutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus | na | May have had a former name of Prezalizumab | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMSWVR QAPGKG LEWVAYIK QDGN EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REG ILWF GDLPTFWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISNWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYCQ QYDSYPRTFGQGT KVEI K |
Pritoxaximab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS | DIVMSQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQNPGQSPKFLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYSSYPLTFGAGTSLELK | na | na | null | null | null | 2,012 | 2013 | Shiga Toxin Type 1 | Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc | na | na | Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections | na | null | QV QLQ ESGA ELVR SGA SVRMSCK ASGY TFTSYNMHWVK QTPGQG LEWIGYIY PGNGGTN YIQKF KG KAILTA DTSSST AYMQISS LTSEDS AVYFCT RSPSHYSSDPYFDYWGQG TTLTVS S | DI VMS QSH KFMS TSVGD RVSITCK ASQDVG TAVAWYQ QNPGQSPK FLIYWA STRHTGVPDRFTGSGSGTD FTLTITN VQS EDLADYFCQQ YSSYP LTF GAGT SLEL K |
Pritumumab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLLESGGDLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAITPSGGSTNYADSVKGRFTISRDNSQNTLYLQMNSLRVEDTAVYICGRVPYRSTWYPLYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIYAASSLHSKVPTQFSGSGSGTDFTLTISSLQPEDFATYYCLQYSTYPITFGGGTKVEIK | na | na | null | null | null | 2,003 | 2004 | Vimentin | UCSD;Nascent Biotech | na | Glioma;Breast cancer;COVID-19 | Pancreatic cancer | na | null | E VQLLE SGGD LV QPGG SLRLSC AASGF TFS NY AMSWVR QAPGKGL EWVSAI TPSGGSTNYADSVK GRFTISR DNSQN TLYLQMNSLRV EDT AVYIC GRVPYRST WYPLY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLAWFQ QKPGKAPK SLIYAA SSLHSKVPT QF SGSGSGTD FTLTISS LQPED F ATYYCLQ YSTYP ITF GGGT KVEI K |
Prolgolimab | Whole mAb | G1 | Lambda | Phase-III | Active | QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQVPGKGLEWVSAIDTGGGRTYYADSVKGRFAISRVNAKNTMYLQMNSLRAEDTAVYYCARDEGGGTGWGVLKDWPYGLDAWGQGTLVTVSS | QPVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTAVFGTGTKLTVL | na | na | null | null | null | 2,018 | 2019 | PDCD1 | Biocad | na | Malignant melanoma;Cervical cancer;Non-small cell lung cancer | Solid tumours | na | null | Q VQLVQS GGG LV QPGG SLRLSCA ASGF TFSSYWMYWVRQ VPGKGL EWVSAID TGGGR TYYAD SVKG RFAISRV NAKNT MYLQMNSL RAEDT AVYYCAR DEGGGTG WGVLK DWPYGLDAWGQG TLVTVS S | QPVLTQP LSVSVA LGQ TARITC GGNNIGSK NVHWYQ QKPGQAP VLVIYR DSNRPSGIPERFSGSNSGN TATLTISR AQAGDE ADYYCQVWD SSTA VF GTGT KLTV L |
Pucotenlimab | Whole mAb | G4 | Kappa | Approved | Active | EVQLVQSGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQAPGKGLDWVATISGGGRDTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCARQKGEAWFAYWGQGTLVTVSS | DIVLTQSPASLAVSPGQRATITCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNKGTGVPARFSGSGSGTDFTLNINPMEENDTAMYFCQQSKEVPWTFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | PDCD1 | Taizhou Hanzhong Pharmaceuticals | Solid tumours | Gastrointestinal cancer;Malignant Melanoma;Non-small cell lung cancer;Bladder cancer;Breast cancer;Liver cancer | na | na | null | E VQLVQS GGG LV QPGG SLKLSC AASGF TFSS YG MSWVRQ APGKGL DWVATIS GGGRDTYYPDSVK GRFTISR DNSKNN LYLQMN SLRAEDT ALYYCAR QKGE AWFAYW GQG TLVTV SS | D IVLTQ SPA SLAV SPGQ RATITCRA SESVDNY GISFMNWF QQKPGQPP KLLIYAA SNKGTGVP ARF SGSGSGT DFTLNI NPMEENDT AMYFCQ QSKEVPW T FGGGT KLEI K |
Pulocimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS | DIQMTQSPSSVSASIGDRVTITCRASQGLDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK | na | na | null | 3s34:HL/3s37:HL/3s36:HL | null | 2,021 | 2022 | VEGFR2 | Akeso Biopharma | na | Solid tumours | na | na | null | E VQLVQS GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV TDAF DI WGQG TMVTVS S | DIQ MT QSPSS VSAS IGD RVTITCR ASQGLDN W LGWYQ QKPGKAP KLLIYD ASNLDTGVPSRFSGSGSGT YFTLTISS LQAED FAVYFCQ QAKAFPPTFGGGT KVDI K |
Quavonlimab | Whole mAb | G1 | Kappa | Phase-I | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWYQRKPGKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNVLRSPFTFGSGTKLEIK | na | na | null | null | null | 2,019 | 2020 | CTLA4 | Merck | na | Non-small cell lung cancer;Malignant melanoma;Renal cell carcinoma;Solid tumours | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SDN WMNWVRQ APGKG LEWLAQI RNKPYNYE TYYSASVKGRFTISR DDSKN SVYLQMNSL KTEDTG VYYCTAQFAY WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR TSENIYGG LNWYQ RKPGKSP KLLIYG ATNLASG VSSRF SGSGSGTD YTLTISS LQP EDVA TYYCQ NVLRSPF T FGSGT KLEI K |
Quetmolimab | Whole mAb | G2 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASGNIHNFLAWYQQKPGKAPKLLIYNEKTLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQFWSTPYTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | CX3CL1 | KAN Research Institute;EA Pharma;Eisai Co Ltd | na | Crohn's disease;Rheumatoid arthritis | Primary biliary cirrhosis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYYIHWVK QAPGQG LEWIGWIY PGDGSPKFNERFKG RTTLTA DKSTN TAYMLLSS LRSEDT AVYFCA TGPTDGD YFDY WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASGN IHNFLAWYQ QKPGKAP KLLIYN EKTLADGVPS R FSGSGSGTD YTLTIS SLQ PEDFATYFCQQF WSTPY T FGGGT KVEI K |
Quilizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGIAWVRQAPGKGLEWVAFISDLAYTIYYADTVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNWDAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQSLVHNNANTYLHWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQNTLVPWTFGQGTKVEIK | na | na | 3hr5:HL:JQ:BA:IP | null | null | 2,011 | 2012 | IGHE | Genentech | na | na | Allergic asthma;Allergic rhinitis;Urticaria | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SDY GIAWVRQ APGKGL EWVAFI SDLA YTIYYA DTVT GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RDNWDAMDYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR SSQS LV HNNANT YLHWYQ QKPGKAP KLLIYKV SNRFSGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYC SQNT LV PW T FGQGT KVEI K |
Quisovalimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYNWHWIRQPPGKGLEWIGEITHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVREIAVAGTGYYGMDVWGQGTTVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQGINSAFAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | TNFSF14 | Avalo Therapeutics | na | Crohn's disease;COVID-19 | na | na | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFSGY NWHWIR QPPGKGL EWIGEITH SGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCVREIAV AGTGY YGMDV WGQG TTVTVS S | AI QLT QSPSS LSAS VGD RVTITCR ASQGIN SAFAWYQ QKPGKAP KLLIYD ASSLESGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGGT KVEI K |
Racotumomab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS | DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK | na | na | null | null | null | 2,008 | 2009 | Idiotope of anti-NeuGc-ganliosides | Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio | Non-small cell lung cancer | Neuroblastoma | Breast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours | na | null | Q VQLQQ SGA ELV KPGA SVKLSCK ASGY TFTSYDINWVR QRPEQGL EWIGWIF PGDGSTKYNEKFKG KATLTT DKSSS TAYMQLSR LTSEDS AVYFCAR EDYYDNS YYFDY WGQG TTLTVS S | DIQ MTQ TTS SLSA SLGD RVTISCR ASQD ISNYLNWYQ QKPDGT VKLLIYYT SRLHSGVPSRFSGSGSGTD YSLTIS NLE QEDIATYFC QQGNTLP WT FGGGT KLEI K |
Radretumab | di-scFv + CH4 | E | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | FN extra domain B | Philogen | na | na | Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease | na | Radretumab+Bifikafusp+Onfekafusp have identical V domains | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSFSMSWVR QAPGKG LEWVSSIS GSSGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPFPYFDYWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSFLAWY Q QKPGQAP RLLIYYA SSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QTGRIPPTFGQGT KVEI K |
Rafivirumab | Whole mAb | G1 | Lambda | Phase-II | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS | QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL | na | na | null | null | null | 2,008 | 2009 | RV Antigenic Site III | Crucell;Sanofi Pasteur | na | na | Rabies | Human Phage Display | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F N RYTVNWVRQ APGQGL EWMGGIIPIF GTANYAQ R FQG RLTITA DESTS TAYMELSS LRSDDT AVYFCAR ENLDNSGT YYYFSGWF DPWGQ GTLVTVS S | QSALTQPR S VSGSPGQ SVTISCT GTSSDIGG YNFVSWYQ QHPGKAP KLMIYD ATKRPSGVPDRFSGSKSGN TASLTIS GLQAEDEAD YYCCS YAGDYTPG VVF GGGT KLTV L |
Ragifilimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMYWVRQAPGQGLEWIGVIRTYSGDVTYNQKFKDRATMTVDKSISTAYMELSRLRSDDTAVYYCAKSGTVRGFAYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYHCQNDYSYPYTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | TNFRSF18 | Incyte | na | Glioblastoma;Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSC KGSGY TF TD YAMYWVRQ APGQGL EWIGVIRTY SGD VTY NQKFKDR ATMTV DKSI STAYMELS RLRSDDT AVYYC AKSG TVRGFAYW GQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINC KSSQ SL LNSGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYHC QNDYSYPY T FGQGT KLEI K |
Ralpancizumab | Whole mAb | G2 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEIHPSGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYHASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK | na | na | null | null | 3sqo:HL | 2,013 | 2014 | PCSK9 | Pfizer | na | na | Hypercholesterolaemia | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGEI HPSGGRTNYNEKF KSRVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RERPL YA SDLWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQD VH TAVAWYQ QKPGKAP KLLIYHASYRY TGVPSRFSGSGSGT DFTFTIS SLQ PEDIATYYCQ QRY SLWRT FGQGT KLEI K |
Raludotatug | Whole mAb | G1 | Kappa | TBC | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFGQGTKVEIK | na | na | null | null | null | 2,022 | na | CDH6 | TBC | TBC | TBC | TBC | TBC | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTR N FMHWVR QAPGQGL EWMGWIY PGDGET EYAQ K FQG RVTITA DTSTS TAYMELS SLRSEDT AVYYCA RGVYGGFAGG YFDF WGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCK ASQN IYKNLAWYQ QKPGKAP KLLIYD ANTL Q TGVPSRFSGSGSGSD FTLTIS SLQ PEDFATYFCQQY YSGW A FGQGT KVEI K |
Ralzapastotug | Whole mAb | G1 | Kappa | TBC | Active | QVQLQESGPGLVKPSGTLSLTCAVSGYSITSGYSWHWVRQPPGKGLEWIGYVHYSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARMDYGNYGGAMDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCKASQDVRTAVAWYQQKPGQAPRLLIYSASYRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYSTQWTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | TIGIT | TBC | TBC | TBC | TBC | TBC | null | QV QLQE SGPG LV KPSG TLSLTCAV SGY SI TSG YSWHWVR QPPGKGL EWIGYVHY SGSTNYNPSLK SRVTISVD KSKN QFSLKLSSV TAADT AVYYCARM DYGNYGGAMDYWGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCK ASQD VR TAVAWYQ QKPGQAP RLLIYSASYRY TGIP ARF SGSGSGT EFTLTISS LQSED FAVYYCQQ YYST QWTF GGG TKVEI K |
Ramucirumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS | DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK | na | na | 3s34:HL/3s37:HL/3s36:HL | null | null | 2,008 | 2009 | KDR | Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine | Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer | Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer | Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma | Dyax Human Phage Display | null | E VQLVQS GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV TDAF DI WGQG TMVTVS S | DIQ MT QSPSS VSAS IGD RVTITCR ASQGIDN W LGWYQ QKPGKAP KLLIYD ASNLDTGVPSRFSGSGSGT YFTLTIS SLQAED FAVYFCQ QAKAFPPTFGGGT KVD IK |
Ranevetmab | Canine Whole mAb | G1 | Kappa | Unknown | Active | EVQLVESGGGLVQPGGSLRLSCVASGFSLTNNNVNWVRQAPGKGLEWVGGVWAGGATDYNSALKSRFTISRDNAKNTVFLQMHSLRSEDTAVYYCARDGGYSSSTLYAMDAWGQGTSVTVSS | DIVMTQSPASLSLSQGETVTITCRASEDIYNALAWYQQKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHYFHYPRTFGQGTKVELK | na | na | null | null | null | 2,016 | 2017 | NGFB | Nexvet | na | Osterarthritis | na | PETization Technology | null | E VQLVES GGG LV QPGG SLRLSCVA SG FS LTNNN VNWVRQ APGKG LEWV GG VWA GGATDYNSALK SRFTIS RDNAKN TVFLQMHS LRSEDT AVYYCA RDGGYSSS TLYAMD AWGQG TSVTVS S | DI VMT QSPA SLSL SQGE TVTITCR AS EDIYNALAWYQ QKPGQAP KLLIYN TDTLHTGVPSRFSGSGSGTD FSLTIS SLEPE D VAVYYCQ HYFHYPRTFGQGT KVEL K |
Ranibizumab | Fab | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | na | na | 1cz8:HL:YX | null | 1bj1:HL:KJ/6bft:HL:AB | 2,004 | 2004 | VEGFA | Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn | Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy | Retinopathy of prematurity;Polypoidal choroidal vasculopathy | Retinal telangiectasis | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGYDF THYGMNWVR QAPGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPYYYGTS HWYFDV WGQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K |
Ravagalimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK | na | na | 6pe7:HL/6pe8:HL:AB | null | 6pe9:AB:CD:EF:HL:KM | 2,017 | 2018 | CD40 | AbbVie | na | Ulcerative colitis;Sjogren's syndrome | Crohn's disease | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFS DYGM NWVRQ APGKGL EWIAYIS SGRGN IYYAD TVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RSWG YFDV WGQG TTVTVS S | D IVMT QSPDS LAVS LGER ATINC KSSQ SLL NRGNQKN YLTWFQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYTYP LTF GQGT KLEI K |
Ravulizumab | Whole mAb | G2 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK | na | na | null | 5i5k:HL:XY | null | 2,017 | 2018 | C5 | Alexion Pharmaceuticals | Paroxysmal nocturnal haemoglobinuria | Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGH IF SN YWIQWVR QAPGQG LEWMGEI LPGSGHT EYT ENFKD RVTMTR DTSTS TVYMELS SLRSEDT AVYYCARYF FGSSPN WYFDVW GQG TLVTVS S | DIQMTQSPSSL SA SVGD RVTITC GASEN IYGALNWYQ QKPGKAP KLLIYG ATNLADGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQN VLNTPL T FGQGT KVEI K |
Recaticimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGYINPSSGFTKYHQNFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARQYDYDEDWYFDVWGQGTTVTVSS | DIVMSQSPSSLSASVGDRVTITCKSSQSLLNSRTRKNFLAWYQQKPGKSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCKQSFNLFTFGQGTKLEIK | na | na | null | null | null | 2,020 | 2021 | PCSK9 | Shanghai Hengrui Pharmaceuticals | na | Hypercholesterolemia | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYWMHWVR QAPGQGL EWMGYI NPSSGFT KY HQNFKDR VTM TRDTS ISTAYMELSR LRSDDT AVYYCARQ YDYDED WYFDVW GQG TTVTVS S | DI VMS QSPSS LSA SVGD RVTITC KSSQ SLL N SRTRKNFLAWYQ QKPGKSPK LLIYWA STRESGVPDRFSGSGSGTD FTLTIS SLQ PEDFAT YYC KQS FNLFTF GQGT KLEI K |
Refanezumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | MAG | GlaxoSmithKline | na | na | CNS trauma;Stroke | na | null | Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TFTN YG MNWVR QAPGQGL EWMGWIN TYTGEPT Y ADDFTG RFVFSL DTSVS TAYLQISS LKAEDT AVYYCA RNPIN Y YG IN YEG YVMDY WGQG TLVTVS S | D IVMT QSPDS LAVS LGE RATINC KSSH SVLYS SNQKN YLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCHQYL SSL T FGQGT KLEI K |
Regdanvimab | Whole mAb | G1 | Lambda | Approved | Active | QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS | ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL | na | na | 7cm4:HL | null | null | 2,020 | 2021 | SARS-CoV-2 Spike RBD | Celltrion | na | COVID-19 | na | na | null | Q ITLK ESGP TLV KPTQ TLTLTCSF SG FSLS TSG VGVGWIR QPPGKA LEWLALID WDDNKY HTTSLKTRLTIS KDTSKN QVVLTMT NMDPVDT ATYYCAR IPG FLRY RNR YYYYGMD VWGQG TTVTVS S | EL VLT QPPS V SAAPGQ KVTISC SGSSSNIGNN YVSWYQ QLPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS ATLGITG LQTGDEAD YYC GTWDSSLSAG VF GGGT ELTV L |